Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01242267 · OUTCOME

Treatment Free Interval/PFS

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT · Source last updated 2026-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Standard Deviation
Time frame
PFS was defined as the time from ASCT to disease progression or death from any cause, an average of 9 months

What was measured

The treatment-free interval after treatment with the combination of thalidomide, bortezomib and melphalan

Analysis population: Data no longer available, only manuscript information where PFS reported for single Arm/Group of all participants

Groups in this outcome

Phase 1/Phase 2

Assessment of PFS made using the entire cohort

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1/Phase 229

Reported measurements

Source class 1
Values in months · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Phase 1/Phase 29.30Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0
        value
        9.3
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
The treatment-free interval after treatment with the combination of thalidomide, bortezomib and melphalan
dispersion Type
Standard Deviation
groups
  1. description
    Assessment of PFS made using the entire cohort
    id
    OG000
    title
    Phase 1/Phase 2
param Type
MEDIAN
population Description
Data no longer available, only manuscript information where PFS reported for single Arm/Group of all participants
reporting Status
POSTED
time Frame
PFS was defined as the time from ASCT to disease progression or death from any cause, an average of 9 months
title
Treatment Free Interval/PFS
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice